Skip to main content
Premium Trial:

Request an Annual Quote

BioTheranostics, Ferrer InCode Ink Distribution Pact

NEW YORK (GenomeWeb News) – BioMerieux subsidiary BioTheranostics said today that it has signed up Spain's Ferrer InCode to market its molecular diagnostic cancer test in Spain, Portugal, Greece, and Venezuela.

Under the agreement, Ferrer InCode will market BioTheranostics’ Theros CancerTYPE ID molecular cancer classifier. The test is a 92-gene assay that oncologists may use in their efforts to manage patients whose primary tumor sites are not known, otherwise known as cancers of unknown primary origin, or CUP.

BioTheranostics said that around three to five percent of cancers diagnosed worldwide are classified as CUP, which can cause doctors difficulties in trying to develop their treatment plans.

Ferrer InCode, the biotech subsidiary of Grupo Ferrer International, plans to begin marketing the tests immediately, BioTheranostics said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.